PTC Therapeutics | PTCT - Ebitda


PTC Therapeutics reported $61.98M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Gilead Sciences USD 3.51B 489M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
TG Therapeutics USD 28.11M 23.58M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -121.37M 70.32M Mar/2026